The performance of model-based versus rule-based phase I clinical trials in oncology: A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 43, Issue 3, 2016, Pages 235-242

  van Brummelen, E M J ^a   Huitema, A D R ^a   van Werkhoven, E ^a   Beijnen, J H ^a,b   Schellens, J H M ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Clinical trial design; Dose escalation trials; Model based trials; Rule based trials; Trial duration; Trial performance

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCURACY; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; FIRST IN HUMAN STUDY; HUMAN; ONCOLOGY; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); POPULATION SIZE; PRIORITY JOURNAL; REVIEW; BIOASSAY; BIOLOGICAL MODEL; COMPUTER SIMULATION; DOSE RESPONSE; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; RESEARCH DESIGN;

EID: 84960431820     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-016-9466-0     Document Type: Review

References (14)

1. Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101(10):708–720
2. Jaki T, Clive S, Weir CJ (2013) Principles of dose finding studies in cancer: a comparison of trial designs. Cancer Chemother Pharmacol 71(5):1107–1114
3. A Iasonos, J O’Quigley (2014) Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol 32(23):2505–2511
4. Le Tourneau C, Gan HK, Razak ARA, Paoletti X (2012) Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. PLoS ONE 7(12):e51039
5. Harrington JA, Wheeler GM, Sweeting MJ, Mander AP, Jodrell DI (2013) Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol 10(5):277–288
6. Mandrekar SJ (2014) Dose-finding trial designs for combination therapies in oncology. J Clin Oncol 32(2):65–67
7. European Medicines Agency Committe for Medicinal Products for Human Use, “Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design,” 2007. [Online]. Available: http://www.ema.europa.eu/docs/
8. U.S. Food and Drug Administration (2010) Guidance for industry: adaptive design clinical trials for drugs and biologics 2010. [Online]. Available: http://www.fda.gov/downloads/Drugs/Guidances/ucm201790.pdf
9. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A (2007) Translation of innovative designs into phase I trials. J Clin Oncol 25(31):4982–4986
10. Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18(3):684–692
11. Zhou Y (2004) Choice of designs and doses for early phase trials. Fundam Clin Pharmacol 18(3):373–378
12. O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46(1):33–48
13. R Core Team (2014) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria., 2014. [Online]. Available: http://www.r-project.org/
14. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U (2013) First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 19(13):3671–3680